ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / XBIT / news
GOSS (28) OSTX (30) RNXT (29) APLM (55) ⌘ Pro Terminal →

Why XBIT Stock surged +2.13% Today — RQD Quant Desk Flash

$1.92 +2.13% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.92

XBiotech Inc. (XBIT) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $58.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on XBIT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is XBIT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, XBiotech Inc. (NASDAQ: XBIT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.92 (+2.13% 1D, market cap $58.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, XBIT ranks #726 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does XBIT compare to GOSS and OSTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XBIT carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GOSS (Gossamer Bio Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $57.8M) and OSTX (OS Therapies Incorporated) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $59.8M). Among the 5-stock peer group, XBIT leads on earnings multiple (N/A) while XBIT leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for XBIT?
▼

Per XBIT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001626878), XBiotech Inc. generated $155.9M in revenue (+31.1% YoY), -$45.5M in net income, and -$40.2M in free cash flow against $150.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.92 (+0.19%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510032
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (6)Whales (3)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.5% Base Target
$4 Bull$2 Base$1 Bear
📬 FREE XBIT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XBIT)Realized 20D OHLCV Swing Band: ±11.4%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY XBIT SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (25% of score)

FRED Regime × Technicals: 7% of 52W Range • RSI-14 at 38.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
40
Grade D$2.16-6.5% Next Q
Q2 (-2Q)
37
Grade E$2.02-8.4% Next Q
Q3 (-1Q)
35
Grade E$1.85+3.8% Next Q
Current
32
Grade E$1.92-9.2% Hist 90D α
Trajectory: D (40) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a XBIT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While XBIT currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.14) and Max Pain ($2.02) forces dealer call-delta covering toward $3.61.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $XBIT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “XBIT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why XBIT Stock surged +2.13% Today — RQD Quant Desk Flash

XBiotech Inc. (XBIT) surged +2.13% to $1.92, trading at 7% of its 52-week range ($1.8 – $3.44). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 7% of its 52-week range ($1.8 – $3.44) with RSI-14 at 38.6 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±11.4% around $1.92 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live XBIT Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XBIT)

  • ✓Walkthrough of XBIT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
XBIT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -24.71%▼ DESCENDING CHANNEL
2026-11-04O $1.88H $1.92L $1.88C $1.92VOL 61.4K
RES: $2.28SUP: $1.78SMA50: $2.14SMA200: $2.32
$2.63$2.41$2.18$1.96$1.73RES $2.28SUP $1.78$1.922026-05-052026-06-182026-08-052026-09-182026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XBIT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XBIT Butterfly Map → + Track XBIT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +31.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on XBIT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XBIT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for XBIT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XBIT)

Health Care Rank #726 of 1015 ⚔️ GOSS vs XBIT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XBIT vs. GOSS, OSTX, RNXT, APLM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, XBiotech Inc. (XBIT) ranks #726 by composite RQD confidence (32/100, grade E) and #717 by equity capitalization ($58.5M). Within this direct 5-issuer industry benchmark cohort, XBIT leads on earnings valuation at N/A trailing P/E, while XBIT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. APLM currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with XBIT at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
XBIT ACTIVE
XBiotech Inc.
E 32/100 — — -35.0% +2.13% $58.5M Benchmark Subject
GOSS
Gossamer Bio Inc.
E 28/100 — — -35.0% -8.96% $57.8M /goss-vs-xbit →
OSTX
OS Therapies Incorporated
E 30/100 — — -35.0% -7.26% $59.8M /ostx-vs-xbit →
RNXT
RenovoRx Inc.
E 29/100 — 70.9% -35.0% -5.26% $56.9M /rnxt-vs-xbit →
APLM
Apollomics Inc. (Class A)
D+ 55/100 — — — +0.73% $60.4M /aplm-vs-xbit →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001626878 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), XBiotech Inc. (XBIT) reported GAAP revenue of $155.9M (+31.1% vs. FY2024 revenue of $118.9M , and +48.5% cumulative change since FY2023) , GAAP net income of -$45.5M, operating cash flow of -$39.9M, and free cash flow of -$40.2M (-24.6% YoY). On the balance sheet, XBIT closed FY2025 with $150.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $155.9M -$45.5M -$39.9M -$40.2M $150.1M —
FY2024 (FY) 2024-12-31 $118.9M -$38.5M -$31.0M -$32.3M $199.1M —
FY2023 (FY) 2023-12-31 $105.0M -$24.6M -$18.7M -$18.7M — —

3. XBIT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XBIT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, XBiotech Inc. (NASDAQ: XBIT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.92 (+2.13% 1D, market cap $58.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, XBIT ranks #726 in composite RQD confidence.

How does XBIT compare to GOSS and OSTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XBIT carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GOSS (Gossamer Bio Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $57.8M) and OSTX (OS Therapies Incorporated) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $59.8M). Among the 5-stock peer group, XBIT leads on earnings multiple (N/A) while XBIT leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XBIT?

Per XBIT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001626878), XBiotech Inc. generated $155.9M in revenue (+31.1% YoY), -$45.5M in net income, and -$40.2M in free cash flow against $150.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XBIT trading relative to its 50-day, 200-day, and 52-week technical levels?

XBIT last traded at $1.92 (+2.13% on volume of 61,446 shares), positioning the stock -10.28% below its 50-day simple moving average ($2.14) and -17.24% below its 200-day simple moving average ($2.32). Across its 52-week range of $1.80 to $3.44, XBIT sits at the 7.3% percentile with a 14-day RSI of 38.6 (NEUTRAL RANGE) and an implied next-earnings move of ±11.4% ($1.70 to $2.14).

Direct Sub-Reports: XBIT RQD Cockpit XBIT 12M Forecast XBIT Earnings & Move XBIT Dividends & DRIP XBIT Insiders & 13F XBIT Whale Options XBIT Profit Sankey XBIT News & Why
ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ SEC XBRL & RQD VERIFIED

XBIT — XBiotech Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

XBiotech Inc. (XBIT) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.92 (+2.13% 1D, market capitalization $58.5M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

XBiotech Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. Reported revenue is — in each FY 2023 through FY 2025 period indicating no reported revenue in the periods provided.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), XBiotech Inc. (XBIT) reported $155.9M in annual revenue (up from $118.9M in FY2024, +31.1% YoY) and -$45.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($105.0M revenue, -$24.6M net income) through FY2025, XBIT scaled operating cash flow to -$39.9M and free cash flow to -$40.2M, backed by $150.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.80 – $3.44 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not establish upstream suppliers, downstream customers, or sector correlations beyond the profile classification. A prospective investor should note that the absence of mapped links means second-order effects cannot be assessed from the provided data.

  • Key Question #1: Can XBIT sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $155.9M and free cash flow of -$40.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is XBIT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

XBIT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for XBiotech Inc. (XBIT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to XBIT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

XBIT Bull vs. Bear Conversation Board — What's Your Call at $1.92?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON XBIT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on XBIT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $2.33 (+23.9%)
📌 Pinned Debate

Market capitalization of $59.1M sits below the $125.6M of reported FY 2025 cash, and a director reportedly bought approximately $711,25

Here is why I am bullish on XBIT here at $1.88: Market capitalization of $59.1M sits below the $125.6M of reported FY 2025 cash, and a director reportedly bought approximately $711,251 of stock.. Compare XBIT's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $1.79 are getting bought.

SectorRotator 🐂 BULL

@RedlineAuditor Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $1.54 (-18.1%)
Spot @ $1.88

ROIC of -35%, FCF of -$40.2M in FY 2025, and zero reported revenue leave no internal cash engine to offset the Piotroski F-Score of 2/9

ROIC of -35%, FCF of -$40.2M in FY 2025, and zero reported revenue leave no internal cash engine to offset the Piotroski F-Score of 2/9.. Look at the math on XBIT: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $1.65 before getting long.

LIVE TAPE